DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

[A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)]

Author(s): Abel T, Feher J

Affiliation(s): Allami Egeszsegugyi Kozpont, Szakrendelo Intezet, Budapest. drabelt@t-online.hu

Publication date & source: 2010-06-20, Orv Hetil., 151(25):1012-6.

Publication type: English Abstract; Review

Type 2 diabetes is a very common worldwide disorder. A good glycemic control is reduce the rates of diabetes associated microvascular and possibly macrovascular complications. Dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin demonstrate an incretin based, glucose-dependent actions with low risk of hypoglycemia and no weight gain during the treatment of patients with type 2 diabetes.

Page last updated: 2010-10-05

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017